Gregg R G, Simantel A, Farrell P M, Koscik R, Kosorok M R, Laxova A, Laessig R, Hoffman G, Hassemer D, Mischler E H, Splaingard M
Waisman Center for Mental Retardation and Human Development, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
Pediatrics. 1997 Jun;99(6):819-24. doi: 10.1542/peds.99.6.819.
To evaluate neonatal screening for cystic fibrosis (CF), including study of the screening procedures and characteristics of false-positive infants, over the past 10 years in Wisconsin. An important objective evolving from the original design has been to compare use of a single-tier immunoreactive trypsinogen (IRT) screening method with that of a two-tier method using IRT and analyses of samples for the most common cystic fibrosis transmembrane regulator (CFTR) (DeltaF508) mutation. We also examined the benefit of including up to 10 additional CFTR mutations in the screening protocol.
From 1985 to 1994, using either the IRT or IRT/DNA protocol, 220 862 and 104 308 neonates, respectively, were screened for CF. For the IRT protocol, neonates with an IRT >/=180 ng/mL were considered positive, and the standard sweat chloride test was administered to determine CF status. For the IRT/DNA protocol, samples from the original dried-blood specimen on the Guthrie card of neonates with an IRT >/=110 ng/mL were tested for the presence of the DeltaF508 CFTR allele, and if the DNA test revealed one or two DeltaF508 alleles, a sweat test was obtained.
Both screening procedures had very high specificity. The sensitivity tended to be higher with the IRT/DNA protocol, but the differences were not statistically significant. The positive predictive value of the IRT/DNA screening protocol was 15.2% compared with 6.4% if the same samples had been screened by the IRT method. Assessment of the false-positive IRT/DNA population revealed that the two-tier method eliminates the disproportionate number of infants with low Apgar scores and also the high prevalence of African-Americans identified previously in our study of newborns with high IRT levels. We found that 55% of DNA-positive CF infants were homozygous for DeltaF508 and 40% had one DeltaF508 allele. Adding analyses for 10 more CFTR mutations has only a small effect on the sensitivity but is likely to add significantly to the cost of screening.
Advantages of the IRT/DNA protocol over IRT analysis include improved positive predictive value, reduction of false-positive infants, and more rapid diagnosis with elimination of recall specimens.
评估过去10年在威斯康星州进行的囊性纤维化(CF)新生儿筛查,包括筛查程序及假阳性婴儿特征的研究。从最初设计演变而来的一个重要目标是比较单层免疫反应性胰蛋白酶原(IRT)筛查方法与使用IRT及分析最常见囊性纤维化跨膜传导调节因子(CFTR)(ΔF508)突变的双层方法的使用情况。我们还研究了在筛查方案中增加多达10种额外CFTR突变的益处。
1985年至1994年,分别使用IRT或IRT/DNA方案对220862名和104308名新生儿进行CF筛查。对于IRT方案,IRT≥180 ng/mL的新生儿被视为阳性,并进行标准汗液氯化物试验以确定CF状态。对于IRT/DNA方案,对IRT≥110 ng/mL的新生儿Guthrie卡片上原始干血标本进行检测,以确定是否存在ΔF508 CFTR等位基因,如果DNA检测显示有一个或两个ΔF508等位基因,则进行汗液试验。
两种筛查程序均具有很高的特异性。IRT/DNA方案的敏感性往往更高,但差异无统计学意义。IRT/DNA筛查方案的阳性预测值为15.2%,而如果用IRT方法对相同样本进行筛查,阳性预测值为6.4%。对IRT/DNA假阳性人群的评估显示,双层方法消除了低阿氏评分婴儿数量过多的情况,也消除了我们之前对高IRT水平新生儿研究中发现的非裔美国人的高患病率。我们发现,55%的DNA阳性CF婴儿为ΔF508纯合子,40%有一个ΔF508等位基因。增加对10种以上CFTR突变的分析对敏感性影响很小,但可能会显著增加筛查成本。
IRT/DNA方案相对于IRT分析的优势包括提高阳性预测值、减少假阳性婴儿以及通过消除召回标本实现更快速的诊断。